Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Read more about Notice of Completion of Acquisition of Own Shares
Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585；Headquarters: Akita; CEO: Tatsuyoshi Hirano) today announced that...
Chertsey, England [23rd May, 2014] Astellas Pharma Europe Ltd. (APEL), the European Headquarters of Tokyo-based Astellas Pharma Inc., today announces a groundbreaking programme, Action on Fistula,...
Tokyo, Japan– May 23, 2014 – Astellas Pharma Inc. (TSE: 4503) announced that oral androgen receptor signaling inhibitor, XTANDI® Capsules 40mg (generic name: enzalutamide) becomes available...
TOKYO, JAPAN and SAN FRANCISCO, CA – MAY 6, 2014 – Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has...
Follow us
